About: ICU-acquired weakness

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: ICU-acquired weakness Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	ICU-acquired weakness
Creator	Vanhorebeek, Ilse Latronico, Nicola Van Den Berghe, Greet
Source	PMC
abstract	Critically ill patients often acquire neuropathy and/or myopathy labeled ICU-acquired weakness. The current insights into incidence, pathophysiology, diagnostic tools, risk factors, short- and long-term consequences and management of ICU-acquired weakness are narratively reviewed. PubMed was searched for combinations of “neuropathy”, “myopathy”, “neuromyopathy”, or “weakness” with “critical illness”, “critically ill”, “ICU”, “PICU”, “sepsis” or “burn”. ICU-acquired weakness affects limb and respiratory muscles with a widely varying prevalence depending on the study population. Pathophysiology remains incompletely understood but comprises complex structural/functional alterations within myofibers and neurons. Clinical and electrophysiological tools are used for diagnosis, each with advantages and limitations. Risk factors include age, weight, comorbidities, illness severity, organ failure, exposure to drugs negatively affecting myofibers and neurons, immobility and other intensive care-related factors. ICU-acquired weakness increases risk of in-ICU, in-hospital and long-term mortality, duration of mechanical ventilation and of hospitalization and augments healthcare-related costs, increases likelihood of prolonged care in rehabilitation centers and reduces physical function and quality of life in the long term. RCTs have shown preventive impact of avoiding hyperglycemia, of omitting early parenteral nutrition use and of minimizing sedation. Results of studies investigating the impact of early mobilization, neuromuscular electrical stimulation and of pharmacological interventions were inconsistent, with recent systematic reviews/meta-analyses revealing no or only low-quality evidence for benefit. ICU-acquired weakness predisposes to adverse short- and long-term outcomes. Only a few preventive, but no therapeutic, strategies exist. Further mechanistic research is needed to identify new targets for interventions to be tested in adequately powered RCTs.
has issue date	2020-02-19(xsd:dateTime)
bibo:doi	10.1007/s00134-020-05944-4
bibo:pmid	32076765
has license	no-cc
sha1sum (hex)	971e46d9a53243b18a0149b33fba3e4c4c73f859
schema:url	https://doi.org/10.1007/s00134-020-05944-4
resource representing a document's title	ICU-acquired weakness
has PubMed Central identifier	PMC7224132
has PubMed identifier	32076765
schema:publication	Intensive Care Med
resource representing a document's body	covid:971e46d9a53243b18a0149b33fba3e4c4c73f859#body_text
is schema:about of	named entity 'reviewed' named entity 'hospitalization' named entity 'myopathy' named entity 'early' named entity 'illness' named entity 'age' named entity 'mechanistic' named entity 'augments' named entity 'Critically' named entity 'PubMed' named entity 'INTENSIVE CARE' named entity 'RISK FACTORS' named entity 'RISK OF' named entity 'CURRENT' named entity 'RESPIRATORY MUSCLES' named entity 'WEIGHT' named entity 'strategies' named entity 'sepsis' named entity 'weakness' named entity 'meta-analyses' named entity 'organ failure' named entity 'burn' named entity 'investigating' named entity 'neuropathy' named entity 'exist' named entity 'minimizing' named entity 'combinations' named entity 'current' named entity 'prevalence' named entity 'insights' named entity 'ill' named entity 'risk factors' named entity 'myofibers' named entity 'quality of life' named entity 'long-term' named entity 'neuropathy' named entity 'neurons' named entity 'ICU' named entity 'RCTs' named entity 'ICU' named entity 'ICU' named entity 'long-term' named entity 'animal studies' named entity 'action potential' named entity 'vancomycin' named entity 'mechanical ventilation' named entity 'small study' named entity 'differential diagnosis' named entity 'abdominal muscles' named entity 'macronutrient' named entity 'myofibers' named entity 'ICU' named entity 'cytokine' named entity 'parenteral nutrition' named entity 'CIM' named entity 'aminoglycosides' named entity 'long-term' named entity 'hospital discharge' named entity 'premorbid' named entity 'CIM' named entity 'glucose' named entity 'ketogenesis' named entity 'insulin' named entity 'ICU' named entity 'confidence intervals' named entity 'ICU' named entity 'catabolic' named entity 'MRC' named entity 'ICU' named entity 'Muscle tone' named entity 'route of administration' named entity 'motor axons' named entity 'ICU' named entity 'MRC' named entity 'CMAP' named entity 'ICU' named entity 'risk factors' named entity 'ICU' named entity 'MRC'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software